Dr. Reddy's Laboratories Ltd - Company Profile
Powered by 
All the sales intelligence you need on Dr. Reddy's Laboratories Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Dr. Reddy's Laboratories Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Dr. Reddy's Laboratories Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s) is an integrated global pharmaceutical company. The company manufactures and markets prescription and over-the-counter finished pharmaceutical products, active pharmaceutical ingredients (API), and intermediates. Dr. Reddy’s offers an array of products including generics, branded generics, biosimilars, and over-the-counter pharmaceutical products. Its products are used in various medical fields such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's serves customers worldwide, providing access to affordable and innovative medicines. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
8-2-337, Road No.3 Banjara Hills, Hyderabad, Telangana, 500-034
Website
www.drreddys.com
Telephone
91 40 49002900
No of Employees
27,527
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DRREDDY (NSE)
Revenue (2025)
$3.9B
3.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-25.8%
(2025 vs 2024)
Market Cap*
$10.1B
Net Profit Margin (2025)
XYZ
-28.1%
(2025 vs 2024)
* As of and is in US$
Dr. Reddy's Laboratories Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Generic Biosimilars | Contract Development and Manufacturing Organization (CDMO) | Colozo |
| Generic Small-Molecule Drugs | Custom Pharma Services | Stugeron |
| Active Pharma Ingredients | Regulatory | Omez |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In April, the company signed an agreement to sell its 100% stake in Svaas Wellness Limited to Enspirit Technology Services Private Limited. |
| 2026 | Asset Disposal | In March, the company sold its Wokadine Portfolio to CORONA Remedies, a pharmaceutical company. |
| 2026 | Contracts/Agreements | In February, the company signed a definitive agreement with Mercury Pharma Group Limited to acquire its trademarks, Progynova and Cyclo-Progynova, and related assets for India. |
Competitor Comparison
| Key Parameters | Dr. Reddy's Laboratories Ltd | Pfizer Inc | Novartis AG | Bayer AG | GSK plc |
|---|---|---|---|---|---|
| Headquarters | India | United States of America | Switzerland | Germany | United Kingdom |
| City | Hyderabad | New York City | Basel | Leverkusen | London |
| State/Province | Telangana | New York | Basel-Stadt | Nordrhein-Westfalen | England |
| No. of Employees | 27,527 | 75,000 | 75,267 | 87,757 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| K. Satish Reddy | Chairman | Executive Board | 2015 | 57 |
| G. V. Prasad | Co-Chairman; Managing Director | Executive Board | 2021 | 64 |
| Erez Israeli | Chief Executive Officer | Senior Management | 2018 | 58 |
| M. V. Narasimham | Chief Financial Officer | Senior Management | 2024 | 56 |
| B. Phanimitra | Chief Digital and Information Officer | Senior Management | 2023 | 46 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer